8-K: Ginkgo Bioworks Warrants Face Delisting Despite Common Stock Compliance

Ginkgo Bioworks' warrants are set to be delisted from the NYSE due to low trading prices, while the company's common stock has regained compliance with listing requirements.

Summary

• Ginkgo Bioworks received notice from the NYSE on September 3, 2024, that its warrants will be delisted due to abnormally low trading prices.
• Trading of the warrants was immediately suspended on September 3, 2024.
• The warrants, previously issued in connection with Soaring Eagle Acquisition Corp.'s IPO, are exercisable for one-fortieth of a share of Class A common stock at $11.50 per warrant.
• The company's Class A common stock, trading under the symbol DNA, will continue to trade on the NYSE unaffected by the warrant delisting.
• On the same day, Ginkgo Bioworks was notified that it has regained compliance with the NYSE's minimum price criteria for its common stock.
• The company was previously notified of non-compliance on May 13, 2024.
• As of August 30, 2024, both the closing price and the 30-day average closing price of the common stock were above $1.00, meeting the NYSE's requirements.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While the common stock regained compliance, the delisting of warrants is a negative signal. Overall, the news is slightly positive due to the common stock compliance.

Positives

• Ginkgo Bioworks has regained compliance with the NYSE's minimum price criteria for its common stock.
• The company's common stock will continue to trade on the NYSE unaffected by the warrant delisting.

Negatives

• Ginkgo Bioworks' warrants will be delisted from the NYSE due to abnormally low trading prices.
• Trading of the warrants was immediately suspended.

Risks

• The delisting of the warrants could negatively impact investor sentiment.
• The low trading price of the warrants indicates a lack of market confidence in that particular security.

Future Outlook

The company's common stock will continue to trade on the NYSE, while the warrants will be delisted.

Industry Context

This announcement highlights the challenges faced by companies in maintaining listing compliance, particularly for securities like warrants that can be more volatile than common stock. It also shows the importance of maintaining a minimum share price to remain listed on major exchanges.

Comparison to Industry Standards

• Many companies, especially those that went public via SPAC mergers, have faced challenges with maintaining their share price above the minimum listing requirements.
• The delisting of warrants is not uncommon when they trade at very low prices, as it can be difficult to maintain an orderly market.
• The fact that the common stock has regained compliance is a positive sign, as it indicates that the company's core business is performing better than the warrants might suggest.

Stakeholder Impact

• Shareholders of the common stock may view the news positively due to the regained compliance.
• Warrant holders will be negatively impacted by the delisting and suspension of trading.

Key Dates

Keywords

delisting, warrants, NYSE, compliance, minimum price, Ginkgo Bioworks, DNA, DNA.WS, common stock